DAPK1 and neoplasm: Silencing of DAPK1 via hypermethylation of its promoter has been suggested to influence tumour progression and metastasis in cancers such as CLL (Raval et al., 2007) and DLBCL (Kristensen et al., 2014) and is a marker of poor survival.